The pharmaceutical company has acquired a 45% stake in Alkahest, which aims to fight diseases using plasma transplants from younger patients.
Alkahest, a US-based biopharmaceutical company working on restoring mental capability in older patients by using blood plasma from younger donors, received $37.5m in funding from pharmaceutical firm Grifols.
Grifols has obtained a 45% stake with the investment, which was made alongside a further $12.5m to fund Alkahest’s development of plasma-based products to treat cognitive decline.
Plasma makes up just over half the volume of blood and is the fluid in which blood cells float. It contains, among other things, proteins,…
